Targeted drug trial for Tough-to-Treat ovarian cancer withdrawn before start
NCT ID NCT06545617
Summary
This study aimed to test a new targeted drug called BAT8006 for women with advanced ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to standard platinum-based chemotherapy. The two-part trial planned to first find a safe and effective dose, then test that dose to see if it could shrink tumors. However, the trial was withdrawn by the sponsor before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PERITONEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.